News & Updates
Filter by Specialty:
Does metoprolol influence exercise haemodynamics in HCM?
Exercise contributes to an abnormal risk in pulmonary capillary wedge pressure (PCWP), but is not affected by metoprolol, in patients with obstructive hypertrophic cardiomyopathy (HCM), results of a study have shown.
Does metoprolol influence exercise haemodynamics in HCM?
26 Apr 2022
Ofatumumab boasts long-term safety in relapsing multiple sclerosis
Treatment with ofatumumab in the long term (approximately 3.5 years) among patients with relapsing multiple sclerosis (MS) is well-tolerated, with no new safety risks found, according to the results of ALITHIOS, presented at the 2022 Annual Meeting of the American Academy of Neurology.
Ofatumumab boasts long-term safety in relapsing multiple sclerosis
26 Apr 2022
Ramucirumab–paclitaxel combo works better against HER2-positive vs -negative gastric cancers
Treatment with the combination of ramucirumab and paclitaxel in the second-line setting appears to yield higher responses among patients with HER2-positive gastric or gastro-oesophageal junction adenocarcinoma than among those with HER2-negative disease, according to a subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16).
Ramucirumab–paclitaxel combo works better against HER2-positive vs -negative gastric cancers
26 Apr 2022
Low-dose aspirin yields no survival benefit in gastric adenocarcinoma
Use of low-dose aspirin appears to have a null effect on the 5-year survival of patients who undergo gastrectomy for gastric adenocarcinoma, a study reports.
Low-dose aspirin yields no survival benefit in gastric adenocarcinoma
24 Apr 2022
Once- on par with twice-daily cilostazol–Ginkgo biloba combo in peripheral arterial disease
In the treatment of ischemic symptoms associated with peripheral arterial disease, the use of once-daily SID142 appears to be as good as twice-daily Renexin while having a favourable safety profile, as shown in a phase III study.
Once- on par with twice-daily cilostazol–Ginkgo biloba combo in peripheral arterial disease
23 Apr 2022
Furmonertinib emerges as potential first-line option for EGFRm NSCLC
Treatment-naïve patients with locally advanced or metastatic EGFR-mutated (EGFRm) non-small-cell lung cancer (NSCLC) experience improved progression-free survival (PFS) when treated with furmonertinib compared with gefitinib, according to results of the phase III FURLONG study.